{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:33:56Z","timestamp":1765823636419,"version":"3.48.0"},"reference-count":28,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T00:00:00Z","timestamp":1647993600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2022,2,3]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Critical questions remain about COVID-19 vaccine effectiveness (VE) in real-world settings, particularly in middle-income countries. We describe a study protocol to evaluate COVID-19 VE in preventing laboratory-confirmed SARS-CoV-2 infection in health workers (HWs) in Albania, an upper-middle-income country.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>In this 12-month prospective cohort study, we enrolled HWs at three hospitals in Albania. HWs are vaccinated through the routine COVID-19 vaccine campaign. Participants completed a baseline survey about demographics, clinical comorbidities, and infection risk behaviours. Baseline serology samples were also collected and tested against the SARS-CoV-2 spike protein, and respiratory swabs were collected and tested for SARS-CoV-2 by RT-PCR. Participants complete weekly symptom questionnaires and symptomatic participants have a respiratory swab collected, which is tested for SARS-CoV-2. At 3, 6, 9 months and 12 months of the study, serology will be collected and tested for antibodies against the SARS-CoV-2 nucleocapsid protein and spike protein. VE will be estimated using a piecewise proportional hazards model (VE=1\u2212HR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Baseline data<\/jats:title>\n                    <jats:p>From February to May 2021, 1504 HWs were enrolled. The median age was 44 (range: 22\u201371) and 78% were female. At enrolment, 72% of participants were seropositive for SARS-CoV-2. 56% of participants were vaccinated with one dose, of whom 98% received their first shot within 4\u2009days of enrolment. All HWs received the Pfizer BNT162b2 mRNA COVID-19 vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol and procedures were reviewed and approved by the WHO Ethical Review Board, reference number CERC.0097A, and the Albanian Institute of Public Health Ethical Review Board, reference number 156. All participants have provided written informed consent to participate in this study. The primary results of this study will be published in a peer-reviewed journal at the time of completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04811391\">NCT04811391<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2021-057741","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T12:45:48Z","timestamp":1648039548000},"page":"e057741","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["COVID-19 vaccine effectiveness among healthcare workers in Albania (COVE-AL): protocol for a prospective cohort study and cohort baseline data"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct04811391","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1024-9120","authenticated-orcid":false,"given":"Shela","family":"Sridhar","sequence":"first","affiliation":[{"name":"Global Health Program, Boston Children's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albana","family":"Fico","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Tirana, Albania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iria","family":"Preza","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Tirana, Albania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Hatibi","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Tirana, Albania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonilda","family":"Sulo","sequence":"additional","affiliation":[{"name":"Southeast European Center for Surveillance and Control of Infectious Disease, Tirana, Albania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Kissling","sequence":"additional","affiliation":[{"name":"Epiconcept SAS, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rovena","family":"Daja","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Tirana, Albania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawi","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"World Health Organization Regional Office for Europe, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo","family":"Lemos","sequence":"additional","affiliation":[{"name":"World Health Organization Regional Office for Europe, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Rubin-Smith","sequence":"additional","affiliation":[{"name":"Global Health Program, Boston Children's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Schmid","sequence":"additional","affiliation":[{"name":"Global Health Program, Boston Children's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela","family":"Vasili","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Tirana, Albania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Valenciano","sequence":"additional","affiliation":[{"name":"EpiConcept, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernille","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"World Health Organization Regional Office for Europe, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Pebody","sequence":"additional","affiliation":[{"name":"World Health Organization Regional Office for Europe, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn E.","family":"Lafond","sequence":"additional","affiliation":[{"name":"CDC Atlanta, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Katz","sequence":"additional","affiliation":[{"name":"World Health Organization Regional Office for Europe, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bino","sequence":"additional","affiliation":[{"name":"Institute of Public Health, Southern European Centre for Surveillance and Control of Infectious Diseases (SECID), Tirana, Albania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,3,23]]},"reference":[{"key":"2025121510320982000_12.3.e057741.1","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121510320982000_12.3.e057741.2","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2020.19328"},{"key":"2025121510320982000_12.3.e057741.3","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1080\/21645515.2017.1356495","article-title":"Vaccine development and trials in low and lower-middle income countries: key issues, advances and future opportunities","volume":"13","author":"Grenham","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2025121510320982000_12.3.e057741.4","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S0140-6736(21)00675-9","article-title":"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)","volume":"397","author":"Hall","year":"2021","journal-title":"The Lancet"},{"key":"2025121510320982000_12.3.e057741.5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmc2101951"},{"key":"2025121510320982000_12.3.e057741.6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121510320982000_12.3.e057741.7","unstructured":"Institute of Statistics, Institute of Public Health, and ICF . Albania demographic and health survey 2017-18. Tirana, Albania: Institute of Statistics, Institute of Public Health, and ICF., 2018."},{"key":"2025121510320982000_12.3.e057741.8","unstructured":"Albania: the latest coronavirus counts, charts and maps. Available: https:\/\/graphics.reuters.com\/world-coronavirus-tracker-and-maps\/countries-and-territories\/albania\/"},{"key":"2025121510320982000_12.3.e057741.9","unstructured":"SAGE Working Group on COVID-19 vaccines . Who SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply."},{"key":"2025121510320982000_12.3.e057741.10","unstructured":"Semini L . Albania carries out 1st vaccinations with donated doses, 2021. ABC News"},{"key":"2025121510320982000_12.3.e057741.11","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2021.S1.200248"},{"key":"2025121510320982000_12.3.e057741.12","unstructured":"World Health Organization, Regional Office for Europe . Cohort study to measure COVID-19 vaccine effectiveness among health workers in the who European region: guidance document, 2021."},{"key":"2025121510320982000_12.3.e057741.13","unstructured":"Bino S . COVID -19 definition, surveillance of COVID -19 in Albania. Tirana, Albania Institute of Public Health; December 2020."},{"key":"2025121510320982000_12.3.e057741.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025121510320982000_12.3.e057741.15","unstructured":"World Health Organization . Laboratory biosafety manual. 3 edn, 2004. https:\/\/www.who.int\/csr\/resources\/publications\/biosafety\/Biosafety7.pdf"},{"key":"2025121510320982000_12.3.e057741.16","unstructured":"TaqPath COVID-19 multiplex diagnostic Solution- US. Available: www.thermofisher.com\/us\/en\/home\/clinical\/clinical-genomics\/pathogen-detection-solutions\/covid-19-sars-cov-2\/multiplex.html"},{"key":"2025121510320982000_12.3.e057741.17","unstructured":"Genomic Sequencing of SARS-CoV-2 . A guide to implementation for maximum impact on public health. Geneva: World Health Organization, 2021."},{"key":"2025121510320982000_12.3.e057741.18","unstructured":"U.S. food and Drug Administration website . Wantai SARS-Co-V-2 Ab Elisa [package insert]. Available: https:\/\/www.fda.gov\/media\/140929\/download"},{"key":"2025121510320982000_12.3.e057741.19","doi-asserted-by":"publisher","DOI":"10.2307\/2529982"},{"key":"2025121510320982000_12.3.e057741.20","doi-asserted-by":"publisher","DOI":"10.15585\/MMWR.MM7013E3"},{"key":"2025121510320982000_12.3.e057741.21","unstructured":"Our World in Data . Coronavirus (COVID-19) Vaccinations- statistics and research. Available: https:\/\/ourworldindata.org\/covid-vaccinations"},{"key":"2025121510320982000_12.3.e057741.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00306-8"},{"key":"2025121510320982000_12.3.e057741.23","doi-asserted-by":"crossref","unstructured":"Sulcebe G , Ylli A , Cenko F K-P . Rapid increase of SARS-CoV-2 seroprevalence during the 2020 pandemic year in the population of the city of Tirana, Albania. medRxiv 2021.doi:10.1101\/2021.02.18.21251776","DOI":"10.1101\/2021.02.18.21251776"},{"key":"2025121510320982000_12.3.e057741.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17317-y"},{"key":"2025121510320982000_12.3.e057741.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00575-4"},{"key":"2025121510320982000_12.3.e057741.26","unstructured":"Bernal JL , Gower C , Gallagher E , et al . Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. Available: https:\/\/khub.net\/documents\/135939561\/430986542\/Effectiveness+of+COVID-19+vaccines+against+the+B16172+variant.pdf\/204c11a4-e02e-11f2-db19-b3664107ac42"},{"key":"2025121510320982000_12.3.e057741.27","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121510320982000_12.3.e057741.28","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMc2119270","article-title":"Effectiveness of BNT162b2 vaccine against omicron variant in South Africa","volume":"386","author":"Collie","year":"2022","journal-title":"N Engl J Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-057741","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:32:23Z","timestamp":1765823543000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-057741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,23]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/bmjopen-2021-057741"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-057741","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}